The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

27 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.EBI
University of Queensland
Peptide inhibitors of the Escherichia coli DsbA oxidative machinery essential for bacterial virulence.EBI
University of Queensland
Structure aided design of chimeric antibiotics.EBI
University of Queensland
Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.EBI
University of Queensland
Protease inhibitors: current status and future prospects.EBI
University of Queensland
Inhibition of S/G2 phase CDK4 reduces mitotic fidelity.EBI
University of Queensland
Antimalarial activity of azadipeptide nitriles.EBI
University of Queensland
Molecular engineering of conotoxins: the importance of loop size to alpha-conotoxin structure and function.EBI
University of Queensland
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.EBI
University of Queensland
Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.EBI
University of Queensland
Profiling the enzymatic properties and inhibition of human complement factor B.EBI
University of Queensland
Enzyme adaptation to inhibitor binding: a cryptic binding site in phenylethanolamine N-methyltransferase.EBI
University of Queensland
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.EBI
University of Queensland
Hormone-like conopeptides - new tools for pharmaceutical design.EBI
University of Queensland
Determining the necessity of phenyl ring π-character in warfarin.EBI
University of Queensland
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.EBI
University of Queensland
Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.EBI
University of Queensland
Herbicide-binding sites revealed in the structure of plant acetohydroxyacid synthase.EBI
University of Queensland
A refined agonist pharmacophore for protease activated receptor 2.EBI
University of Queensland
Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter.EBI
University of Queensland
Fused bicyclic pyrimidine derivatives and uses thereofBDB
University of Colorado
BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTIONBDB
Reviral
Thiazoles as modulators of RORγtBDB
Janssen Pharmaceutica
Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.BDB
Philipps-Universität Marburg
Multisubstituted aromatic compounds as serine protease inhibitorsBDB
Verseon
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.BDB
Glaxo Wellcome Research and Development